Weight Gain for HIV Patients Switched to Integrase Inhibitors

Virally suppressed patients who switched from an efavirenz regimen to an integrase inhibitor regimen gained an average of 2.9 kg at 18 months.

Integrase strand transfer inhibitor (INSTI)-based therapies are increasingly favored over earlier antiretroviral therapy (ART) regimens because of their favorable efficacy and safety profiles. However, long-term experience with INSTI regimens is still relatively limited.

After observing weight gain in several HIV patients who switched treatment regimens from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), investigators at Vanderbilt conducted a retrospective analysis of 495 patients who had received EFV/TDF/FTC for ≥2 years and had achieved virologic suppression. Of these, 136 switched to an INSTI regimen, 34 switched to a protease-inhibitor (PI) regimen, and 325 remained…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Weight Gain for HIV Patients Switched to Integrase Inhibitors

Topics

Reviewing Author